دورية أكاديمية
أعرض في EDS

The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.

التفاصيل البيبلوغرافية
العنوان: The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
المؤلفون: Sia TY; Memorial Sloan Kettering Cancer Center, New York, NY, United States of America. Electronic address: siat@mskcc.org., Tew WP; Memorial Sloan Kettering Cancer Center, New York, NY, United States of America. Electronic address: teww@mskcc.org., Purdy C; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America. Electronic address: purdyc@nrgoncology.org., Chi DS; Memorial Sloan Kettering Cancer Center, New York, NY, United States of America. Electronic address: chid@mskcc.org., Menzin AW; North Shore-Long Island Jewish Medical Center, Manhasset, NY, United States of America. Electronic address: amenzin@northwell.edu., Lovecchio JL; North Shore-Long Island Jewish Medical Center, Manhasset, NY, United States of America. Electronic address: jlovecch@northwell.edu., Bookman MA; Gynecologic Oncology Therapeutics, Kaiser Permanente, San Francisco, CA, United States of America. Electronic address: Michael.A.Bookman@kp.org., Cohn DE; Ohio State University Comprehensive Cancer Center, Columbus, OH, United States of America. Electronic address: David.Cohn@osumc.edu., Teoh DG; University of Minnesota Medical Center, Minneapolis, MN, United States of America. Electronic address: dkteoh@umn.edu., Friedlander M; Department of Medical Oncology, Prince of Wales Hospital and Prince of Wales Clinical School, UNSW, Sydney, New South Wales, Australia. Electronic address: Michael.Friedlander@health.nsw.gov.au., Bender D; University of Iowa Hospitals, Iowa City, IA, United States of America. Electronic address: David-bender@uiowa.edu., Mutch DG; Washington University, St. Louis, MO, United States of America. Electronic address: mutchd@wustl.edu., Gershenson DM; MD Anderson Cancer Center, Houston, TX, United States of America. Electronic address: dgershen@mdanderson.org., Tewari KS; University of California, Irvine, Orange, CA, United States of America. Electronic address: ktewari@hs.uci.edu., Wenham RM; Moffitt Cancer Center and Research Institute, Tampa, FL, United States of America. Electronic address: Robert.wenham@moffitt.org., Wahner Hendrickson AE; Mayo Clinic, Rochester, MN, United States of America. Electronic address: WahnerHendrickson.Andrea@mayo.edu., Lee RB; Tacoma General Hospital, Tacoma, WA, United States of America. Electronic address: rogerblee@aol.com., Gray HJ; Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America. Electronic address: hgray@uw.edu., Secord AA; Duke University Medical Center, Durham, NC, United States of America. Electronic address: angeles.secord@duke.edu., Van Le L; University of North Carolina, Chapel Hill, NC, United States of America. Electronic address: linda_van_le@med.unc.edu., Lichtman SM; Memorial Sloan Kettering Cancer Center, New York, NY, United States of America. Electronic address: LichtmaS@mskcc.org.
المصدر: Gynecologic oncology [Gynecol Oncol] 2023 Jun; Vol. 173, pp. 130-137. Date of Electronic Publication: 2023 May 04.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, Academic Press.
مواضيع طبية MeSH: Ovarian Neoplasms*/pathology , Neoplasms, Glandular and Epithelial*/drug therapy, Female ; Humans ; Aged ; Carcinoma, Ovarian Epithelial/drug therapy ; Carboplatin ; Disease-Free Survival ; Paclitaxel ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Neoplasm Staging
مستخلص: Objective: To assess the effect of age on overall survival (OS) in women with ovarian cancer receiving chemotherapy. Secondary objectives were to describe the effect of age on treatment compliance, toxicities, progression free survival (PFS), time from surgery to chemotherapy, and rates of optimal cytoreduction.
Methods: Women enrolled in GOG 0182-ICON5 with stage III or IV epithelial ovarian cancer (EOC) who underwent surgery and chemotherapy between 2001 and 2004 were included. Patients were divided into ages <70 and ≥ 70 years. Baseline characteristics, treatment compliance, toxicities, and clinical outcomes were compared.
Results: We included a total of 3686 patients, with 620 patients (16.8%) ≥ 70 years. OS was 37.2 months in older compared to 45.0 months in younger patients (HR 1.21, 95% CI, 1.09-1.34, p < 0.001). Older patients had an increased risk of cancer-specific-death (HR 1.16, 95% CI, 1.04-1.29) as well as non-cancer related deaths (HR 2.78, 95% CI, 2.00-3.87). Median PFS was 15.1 months in older compared to 16.0 months in younger patients (HR 1.10, 95% CI, 1.00-1.20, p = 0.056). In the carboplatin/paclitaxel arm, older patients were just as likely to complete therapy and more likely to develop grade ≥ 2 peripheral neuropathy (35.7 vs 19.7%, p < 0.001). Risk of other toxicities remained equal between groups.
Conclusions: In women with advanced EOC receiving chemotherapy, age ≥ 70 was associated with shorter OS and cancer specific survival. Older patients receiving carboplatin and paclitaxel reported higher rates of grade ≥ 2 neuropathy but were not more likely to suffer from other chemotherapy related toxicities. Clintrials.gov: NCT00011986.
Competing Interests: Declaration of Competing Interest Each coauthor must complete an icmje form so that this page can be completed.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
References: J Clin Oncol. 2009 Mar 20;27(9):1419-25. (PMID: 19224846)
JAMA Oncol. 2021 Jun 01;7(6):853-861. (PMID: 33885718)
Gynecol Oncol. 2015 Jun;137(3):401-5. (PMID: 25839911)
J Clin Oncol. 2014 Aug 20;32(24):2553-61. (PMID: 25071129)
Gynecol Oncol. 2019 Apr;153(1):68-73. (PMID: 30612784)
Int J Gynecol Cancer. 2003 Nov-Dec;13(6):735-40. (PMID: 14675308)
Gynecol Oncol. 2020 Nov;159(2):426-433. (PMID: 32868087)
Gynecol Oncol. 2017 Mar;144(3):459-467. (PMID: 28089376)
J Clin Oncol. 2003 Sep 1;21(17):3194-200. (PMID: 12860964)
Gynecol Oncol. 2018 May;149(2):270-274. (PMID: 29514738)
Br J Cancer. 2008 Apr 8;98(7):1197-203. (PMID: 18349836)
J Clin Oncol. 2011 Sep 1;29(25):3457-65. (PMID: 21810685)
J Clin Oncol. 2002 Dec 15;20(24):4636-42. (PMID: 12488407)
Curr Treat Options Oncol. 2013 Mar;14(1):12-21. (PMID: 23197271)
J Clin Oncol. 2019 Jun 1;37(16):1380-1390. (PMID: 31002578)
J Geriatr Oncol. 2016 Sep;7(5):354-61. (PMID: 27499341)
Gynecol Oncol. 2002 Sep;86(3):274-8. (PMID: 12217748)
J Clin Oncol. 2006 Jan 1;24(1):45-51. (PMID: 16382112)
Cancer Biol Med. 2015 Dec;12(4):292-301. (PMID: 26779366)
Gynecol Oncol. 2006 Feb;100(2):417-21. (PMID: 16336992)
JAMA Netw Open. 2020 Sep 1;3(9):e2017517. (PMID: 32975569)
Cancer. 2003 Feb 15;97(4):1107-14. (PMID: 12569613)
Jpn J Clin Oncol. 2008 Jun;38(6):445-50. (PMID: 18508785)
Ann Oncol. 1999;10 Suppl 1:17-20. (PMID: 10219448)
J Clin Oncol. 2002 Jan 1;20(1):173-8. (PMID: 11773167)
Gynecol Oncol. 2015 Apr;137(1):98-101. (PMID: 25602715)
Cancer. 1994 Jan 15;73(2):377-83. (PMID: 8293403)
Lancet Oncol. 2015 Aug;16(8):928-36. (PMID: 26115797)
J Clin Oncol. 2020 Oct 1;38(28):3325-3348. (PMID: 32663120)
J Natl Cancer Inst. 2000 May 3;92(9):699-708. (PMID: 10793106)
Gynecol Oncol. 2012 Jul;126(1):20-4. (PMID: 22522190)
N Engl J Med. 2019 Dec 19;381(25):2416-2428. (PMID: 31851799)
N Engl J Med. 2011 Dec 29;365(26):2473-83. (PMID: 22204724)
N Engl J Med. 1996 Jan 4;334(1):1-6. (PMID: 7494563)
Gynecol Oncol. 2017 Oct;147(1):104-109. (PMID: 28734497)
معلومات مُعتمدة: U10 CA180868 United States CA NCI NIH HHS; UG1 CA233290 United States CA NCI NIH HHS; P30 CA008748 United States CA NCI NIH HHS; UG1 CA233373 United States CA NCI NIH HHS; UG1 CA233191 United States CA NCI NIH HHS; U10 CA180888 United States CA NCI NIH HHS; U10 CA180822 United States CA NCI NIH HHS; UG1 CA233339 United States CA NCI NIH HHS
سلسلة جزيئية: ClinicalTrials.gov NCT00011986
المشرفين على المادة: BG3F62OND5 (Carboplatin)
P88XT4IS4D (Paclitaxel)
تواريخ الأحداث: Date Created: 20230506 Date Completed: 20230602 Latest Revision: 20240603
رمز التحديث: 20240603
مُعرف محوري في PubMed: PMC10414765
DOI: 10.1016/j.ygyno.2023.03.018
PMID: 37148580
قاعدة البيانات: MEDLINE
الوصف
تدمد:1095-6859
DOI:10.1016/j.ygyno.2023.03.018